211 related articles for article (PubMed ID: 26160844)
1. Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis.
Duckworth CA; Guimond SE; Sindrewicz P; Hughes AJ; French NS; Lian LY; Yates EA; Pritchard DM; Rhodes JM; Turnbull JE; Yu LG
Oncotarget; 2015 Sep; 6(27):23671-87. PubMed ID: 26160844
[TBL] [Abstract][Full Text] [Related]
2. Interaction with the heparin-derived binding inhibitors destabilizes galectin-3 protein structure.
Sindrewicz P; Yates EA; Turnbull JE; Lian LY; Yu LG
Biochem Biophys Res Commun; 2020 Mar; 523(2):336-341. PubMed ID: 31866013
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.
Sudha T; Phillips P; Kanaan C; Linhardt RJ; Borsig L; Mousa SA
Clin Exp Metastasis; 2012 Jun; 29(5):431-9. PubMed ID: 22415710
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin.
Nangia-Makker P; Hogan V; Honjo Y; Baccarini S; Tait L; Bresalier R; Raz A
J Natl Cancer Inst; 2002 Dec; 94(24):1854-62. PubMed ID: 12488479
[TBL] [Abstract][Full Text] [Related]
5. Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions.
Wei M; Tai G; Gao Y; Li N; Huang B; Zhou Y; Hao S; Zeng X
J Biol Chem; 2004 Jul; 279(28):29202-10. PubMed ID: 15133030
[TBL] [Abstract][Full Text] [Related]
6. Study on anti-metastasis of heparin derivatives as ligand antagonist of p-selectin.
Li Y; Luo JY; Cui HF; Zheng L; Du SS
Biomed Pharmacother; 2010 Dec; 64(10):654-8. PubMed ID: 20970300
[TBL] [Abstract][Full Text] [Related]
7. Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity.
André S; Kojima S; Yamazaki N; Fink C; Kaltner H; Kayser K; Gabius HJ
J Cancer Res Clin Oncol; 1999; 125(8-9):461-74. PubMed ID: 10480338
[TBL] [Abstract][Full Text] [Related]
8. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.
Rao NV; Argyle B; Xu X; Reynolds PR; Walenga JM; Prechel M; Prestwich GD; MacArthur RB; Walters BB; Hoidal JR; Kennedy TP
Am J Physiol Cell Physiol; 2010 Jul; 299(1):C97-110. PubMed ID: 20375277
[TBL] [Abstract][Full Text] [Related]
9. Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3.
Srinivasan N; Bane SM; Ahire SD; Ingle AD; Kalraiya RD
Glycoconj J; 2009 May; 26(4):445-56. PubMed ID: 18949555
[TBL] [Abstract][Full Text] [Related]
10. Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung.
Ono K; Ishihara M; Ishikawa K; Ozeki Y; Deguchi H; Sato M; Hashimoto H; Saito Y; Yura H; Kurita A; Maehara T
Br J Cancer; 2002 Jun; 86(11):1803-12. PubMed ID: 12087470
[TBL] [Abstract][Full Text] [Related]
11. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Schlesinger M; Schmitz P; Zeisig R; Naggi A; Torri G; Casu B; Bendas G
Thromb Res; 2012 May; 129(5):603-10. PubMed ID: 22099706
[TBL] [Abstract][Full Text] [Related]
12. Lactulose as a novel template for anticancer drug development targeting galectins.
Kishor C; Ross RL; Blanchard H
Chem Biol Drug Des; 2018 Oct; 92(4):1801-1808. PubMed ID: 29888844
[TBL] [Abstract][Full Text] [Related]
13. Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface.
Zhao Q; Guo X; Nash GB; Stone PC; Hilkens J; Rhodes JM; Yu LG
Cancer Res; 2009 Sep; 69(17):6799-806. PubMed ID: 19690136
[TBL] [Abstract][Full Text] [Related]
14. O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.
Borgenström M; Wärri A; Hiilesvuo K; Käkönen R; Käkönen S; Nissinen L; Pihlavisto M; Marjamäki A; Vlodavsky I; Naggi A; Torri G; Casu B; Veromaa T; Salmivirta M; Elenius K
Semin Thromb Hemost; 2007 Jul; 33(5):547-56. PubMed ID: 17629853
[TBL] [Abstract][Full Text] [Related]
15. Chemically modified heparin inhibits the in vitro adhesion of nonsmall cell lung cancer cells to P-selectin.
Gao Y; Wei M; Zheng S; Ba X; Hao S; Zeng X
J Cancer Res Clin Oncol; 2006 Apr; 132(4):257-64. PubMed ID: 16331491
[TBL] [Abstract][Full Text] [Related]
16. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins.
Wang L; Brown JR; Varki A; Esko JD
J Clin Invest; 2002 Jul; 110(1):127-36. PubMed ID: 12093896
[TBL] [Abstract][Full Text] [Related]
17. Chemically modified heparin inhibits in vitro L-selectin-mediated human ovarian carcinoma cell adhesion.
Chen Z; Jing Y; Song B; Han Y; Chu Y
Int J Gynecol Cancer; 2009 May; 19(4):540-6. PubMed ID: 19509548
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression.
Wang L; Li YS; Yu LG; Zhang XK; Zhao L; Gong FL; Yang XX; Guo XL
Biochem Pharmacol; 2020 Aug; 178():114113. PubMed ID: 32579956
[TBL] [Abstract][Full Text] [Related]
19. Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium.
Chen C; Duckworth CA; Zhao Q; Pritchard DM; Rhodes JM; Yu LG
Clin Cancer Res; 2013 Apr; 19(7):1693-704. PubMed ID: 23401226
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
